Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,875,489
  • Shares Outstanding, K 158,759
  • Annual Sales, $ 329,000 K
  • Annual Income, $ 23,380 K
  • EBIT $ 103 M
  • EBITDA $ 98 M
  • 60-Month Beta 1.86
  • Price/Sales 9.29
  • Price/Cash Flow 246.24
  • Price/Book 7.72

Options Overview Details

View History
  • Implied Volatility 52.91% (-4.21%)
  • Historical Volatility 40.84%
  • IV Percentile 8%
  • IV Rank 15.47%
  • IV High 111.36% on 07/10/25
  • IV Low 42.22% on 11/05/25
  • Expected Move (DTE 34) 3.37 (11.01%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 5,237
  • Volume Avg (30-Day) 4,878
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 108,845
  • Open Int (30-Day) 93,587
  • Expected Range 27.20 to 33.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.38
  • Number of Estimates 5
  • High Estimate 0.45
  • Low Estimate 0.27
  • Prior Year 0.15
  • Growth Rate Est. (year over year) +153.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.89 +13.69%
on 01/13/26
33.24 -8.03%
on 01/14/26
-0.22 (-0.71%)
since 12/16/25
3-Month
26.89 +13.69%
on 01/13/26
36.65 -16.59%
on 10/31/25
-4.30 (-12.33%)
since 10/16/25
52-Week
25.28 +20.93%
on 08/11/25
46.48 -34.23%
on 05/01/25
+1.43 (+4.91%)
since 01/16/25

Most Recent Stories

More News
Stock Indexes Settle Lower on Tech Weakness

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.07%. March...

MSTR : 173.71 (+1.64%)
GOOGL : 330.00 (-0.84%)
MPC : 175.63 (-1.10%)
GLXY : 34.31 (+7.25%)
RIVN : 16.67 (-2.29%)
ABNB : 130.66 (-1.46%)
COIN : 241.15 (+0.78%)
TGTX : 30.57 (-0.46%)
OXY : 42.70 (-1.09%)
TSLA : 437.50 (-0.24%)
^BTCUSD : 95,201.77 (-0.34%)
SPY : 691.66 (-0.08%)
Stocks Retreat as Big Tech Falters

The S&P 500 Index ($SPX ) (SPY ) today is down -0.96%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. March E-mini S&P futures...

MSTR : 173.71 (+1.64%)
GOOGL : 330.00 (-0.84%)
MPC : 175.63 (-1.10%)
GLXY : 34.31 (+7.25%)
RIVN : 16.67 (-2.29%)
COIN : 241.15 (+0.78%)
TGTX : 30.57 (-0.46%)
OXY : 42.70 (-1.09%)
TSLA : 437.50 (-0.24%)
^BTCUSD : 95,201.77 (-0.34%)
SPY : 691.66 (-0.08%)
META : 620.25 (-0.09%)
Stocks Pressured by Tech Weakness and Iran Tensions

The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.22%. March E-mini S&P futures...

AMAT : 327.01 (+2.49%)
GOOGL : 330.00 (-0.84%)
MPC : 175.63 (-1.10%)
AVGO : 351.71 (+2.53%)
CVX : 166.26 (+0.06%)
FN : 494.45 (-0.63%)
RIVN : 16.67 (-2.29%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
MSFT : 459.86 (+0.70%)
TGTX : 30.57 (-0.46%)
OXY : 42.70 (-1.09%)
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594...

TGTX : 30.57 (-0.46%)
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 44 th...

TGTX : 30.57 (-0.46%)
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8...

TGTX : 30.57 (-0.46%)
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX),   today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology,...

TGTX : 30.57 (-0.46%)
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the TD...

TGTX : 30.57 (-0.46%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 30.57 (-0.46%)
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI...

TGTX : 30.57 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 32.06
2nd Resistance Point 31.66
1st Resistance Point 31.11
Last Price 30.57
1st Support Level 30.16
2nd Support Level 29.76
3rd Support Level 29.21

See More

52-Week High 46.48
Fibonacci 61.8% 38.38
Fibonacci 50% 35.88
Fibonacci 38.2% 33.38
Last Price 30.57
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar